Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Pembrolizumab shows a moderate benefit over current care, with statistically significant improvements in recurrence-free survival (HR 0.59) and distant metastases-free survival (HR 0.60) compared to placebo. However, overall survival data remains immature, limiting the strength of the evidence.
Cost effectiveness
The most conservative ICER estimate is £26,493 per QALY gained, which is within acceptable thresholds for Healthcare resources. The committee concluded that pembrolizumab is a cost-effective use of resources, especially considering its administration schedule.
Quality of life
While specific HRQoL data is not detailed, the committee noted that recurrence-free survival is a significant outcome for patients, indicating a moderate improvement in quality of life associated with the treatment.
Supporting Domains
Safety and Adverse Effects
Pembrolizumab is generally well tolerated, with 80% of patients experiencing no toxicity. However, there are notable risks of high toxicity (5-10%), which require careful monitoring, but overall, the safety profile is favorable compared to existing therapies.
Comparator Selection
The treatment was compared against placebo in a well-designed RCT (KEYNOTE-054), which is appropriate given the context of adjuvant therapy for melanoma. The committee acknowledged the relevance of the comparator.
Patient Population and Subgroups
The trial population is moderately representative of the intended patient population, with a median age of 53.9 years and a significant proportion of patients with BRAF mutations. However, some subgroup data is limited.
Care Pathway Integration
Pembrolizumab can be integrated into existing care pathways with minor adjustments, as it is administered every 6 weeks, which is preferable for patients compared to other treatments like nivolumab.
Resource Use and Cost Implications
The treatment is expected to have a manageable budget impact, especially considering the potential reduction in administration costs due to less frequent dosing compared to alternatives.
Evidence Quality and Robustness
The evidence is based on a robust RCT design (KEYNOTE-054) with a significant sample size (1,019 participants). However, the immaturity of overall survival data introduces some methodological concerns.
Uncertainty, Sensitivity, and Broader Impacts
There is high uncertainty regarding overall survival estimates due to the ongoing nature of the trial and the reliance on surrogate endpoints. This uncertainty may affect decision-making and restrict use.
